-
The clinical insights gained from T-cell receptor sequencing in revealing the immune characteristics of liver cancer staging
T lymphocytes play a crucial role in human adaptive immunity by recognizing antigens major histocompatibility complex (MHC) molecules through specific T-cell receptors (TCRs) on their surface. 95% of T cells have TCRs composed of α and β peptide chains connected by disulfide bonds, forming an α/β heterodimer. Each chain consists of constant and variable domains.…
-
Dr. Zhang Huilai Interpreted Multiple Studies by His Team at ICML 2023
Editor’s Note: The 17th International Conference on Malignant Lymphoma (ICML) took place from June 13 to 17, 2023, in Lugano, Switzerland. As the largest international conference in the field of…
-
APASL 2023 | Prof. Rao Huiying: Eliminating HCV, Key Issues That Still Need Attention
Chronic HCV infection is a global public health issue. With the widespread use of direct-acting antiviral agents (DAAs), chronic hepatitis C (CHC) has become a curable disease. However, after successful HCV clearance and achieving sustained virological response (SVR), do CHC patients still face risks of liver-related events? Currently, there is a significant gap in reaching…
-
APASL 2023 | Prof. George Lau: Seeking the “Cure” for Liver Disease – A Hepatologist’s Thirty-Year Journey of Exploration
The 32nd annual meeting of the Asia-Pacific Association for the Study of the Liver (APASL) was held at the Taipei International Convention Center in Taiwan, China, from February 15 to 19, 2023. During the conference, the APASL Executive Committee awarded four prestigious honors, including the third APASL Highest Honor Award, the Okuda-Omata Outstanding Achievement Award,…
-
APASL 2023 | Prof. Jia Jidong: Latest Advances in Primary Biliary Cholangitis
Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease mediated by autoimmunity, with its pathogenesis not yet fully understood. Traditionally, PBC was thought to predominantly affect Western populations, but in recent decades, there has been an increasing number of reported cases and published literature in the Asia-Pacific region, escalating the disease burden. In response,…
-
ASH 2023丨Professor Lin Tongyu: Decoding ASH Conference Insights on Lymphoma Treatment, Potential Revealed in r/r-PTCL with EZH1/2 Inhibitor HH2853
From December 9 to 12, the highly anticipated 65th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA. Focused on the annual pinnacle in the field of hematologic malignancies, the front-line reporting team of “Oncology Insights” delved into the forefront, witnessing the outstanding performance of “China’s Good Voice” on the international…
-
ASH Exclusive Interview | Professor Junmin Li: Addition of Homoharringtonine Improves Induction Therapy Efficacy in Low to Intermediate-Risk AML Patients with Chemotherapy Insensitivity
Acute myeloid leukemia (AML) is a highly heterogeneous group with varying sensitivities to chemotherapy. The “7+3” regimen has been the standard induction chemotherapy for AML for 50 years. In the era of precision medicine, optimizing induction therapy for AML is a crucial issue. At the recent 65th American Society of Hematology (ASH) Annual Meeting, Professor…
-
ASH Big Shot Interview | Professor Jie Jin : IL1RAP-TCE Antibody Effectively Eliminates Leukemia Stem Cells in AML
From December 9 to 12, 2023, the 65th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, in a hybrid format combining online and offline sessions. As one of the largest and most comprehensive international academic conferences in the field of hematology, experts and scholars from around the world gathered…
Connecting Medical Expertise through Media